Wall Street is positive on NeoGenomics, Inc. (NEO). On average, analysts give the stock a Strong Buy rating. The average price target is $51.625, which means analysts expect the stock to gain by 38.37% over the next twelve months. That average ranking earns the stock an Analyst Rating of 59, which is better than 59% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating NEO a Strong Buy today. Find out what this means to you and get the rest of the rankings on NEO!